Medicenna Therapeutics (TSE:MDNA) Reaches New 1-Year Low – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA) hit a new 52-week low during trading on Tuesday . The stock traded as low as C$0.42 and last traded at C$0.44, with a volume of 105945 shares traded. The stock had previously closed at C$0.45.

Medicenna Therapeutics Stock Performance

The company’s 50-day moving average is C$0.61 and its two-hundred day moving average is C$0.91. The company has a market capitalization of C$36.70 million, a P/E ratio of -2.93 and a beta of 2.90. The company has a quick ratio of 4.65, a current ratio of 2.68 and a debt-to-equity ratio of 3.30.

Medicenna Therapeutics (TSE:MDNA) last announced its earnings results on Thursday, April 30th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. Equities analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.